Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-Teran, Carlos, Tiruthani, Karthik, McSweeney, Morgan, Ma, Alice, Pickles, Raymond, Lai, Samuel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833882/
https://www.ncbi.nlm.nih.gov/pubmed/33309815
http://dx.doi.org/10.1016/j.addr.2020.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833882/
https://www.ncbi.nlm.nih.gov/pubmed/33309815
http://dx.doi.org/10.1016/j.addr.2020.12.004

Ejemplares similares